Last updated: February 15, 2026
Market Analysis and Price Projections for NDC 00115-2622
Product Overview
NDC 00115-2622 corresponds to the drug Avinza (morphine sulfate extended-release capsules). This medication is used to manage severe pain in opioid-tolerant patients requiring around-the-clock opioid analgesia. It is a prescription-only product approved by the FDA.
Market Landscape
1. Market Size and Demand
- The global opioid analgesics market was valued at approximately $13.9 billion in 2022 and is projected to grow at a CAGR of 4.8% through 2030 (Grand View Research).
- Morphine formulations, including extended-release variants like Avinza, constitute a substantial share of this market due to chronic pain management needs.
- In the United States, the opioid prescription rate peaked in 2012 but has declined owing to regulatory efforts, yet demand persists for formulations suitable for sustained release.
2. Key Competitors
- MS Contin (morphine sulfate ER, marketed by Purdue Pharma).
- Avinza (Pfizer/Eli Lilly).
- Kadian (morphine sulfate ER, Actavis).
- Generic formulations from multiple producers.
3. Regulatory Environment
- The opioid market faces increasing regulatory oversight aimed at limiting misuse and diversion.
- Extended-release formulations are scrutinized for abuse potential but remain integral for certain patient populations.
- The rescheduling of opioids and tighter prescribing guidelines influence market volume.
4. Prescription Trends
- While overall opioid prescriptions declined 30% from 2012-2022, prescriptions for ER formulations like Avinza remained stable due to their clinical utility in managing chronic pain.
- Transition toward abuse-deterrent formulations influences market dynamics but has limited impact on Avinza as it is not yet reformulated with deterrent technologies.
Price Analysis
1. Current Pricing Dynamics
- The average wholesale price (AWP) for Avinza 30 mg capsules is approximately $13.50 per capsule as of early 2023.
- The per-unit cost varies based on strength; for example:
- 30 mg capsules: ~$13.50 each.
- Higher doses (60 mg): approximately $26.00 per capsule.
- Generic morphine ER products are priced about 20-30% lower; for example, generic ER morphine may retail at $9–$10 per capsule.
2. Reimbursement and Patient Cost
- Insurance reimbursement rates typically cover 80–100% of the AWP, depending on payer policies and negotiated discounts.
- Patient co-pays range from $5–$50, influencing utilization patterns.
3. Price Trends
- Prices have remained relatively stable over the past three years, with minor fluctuations driven by manufacturing costs and regulatory pressures.
- The entry of generic versions could reduce average prices by approximately 25%–30% over the next 2–3 years, assuming patent expiry.
Patent and Patent Landscape
- Pfizer's patent for Avinza expired in 2009, leading to generic competition, but some forms of extended-release formulations or formulation-specific patents could impede immediate generic entry.
- The patent landscape for ER morphine formulations is complex, with multiple type-specific patents expiring between 2008 and 2020.
Market and Price Projection (2023–2028)
| Year |
Market Size (USD billion) |
Projected Growth Rate |
Estimated Price per Capsule (USD) |
Major Influences |
| 2023 |
14.2 |
4.8% |
$13.50 (brand) / $9–$10 (generic) |
Regulatory environment, patent expiry |
| 2024 |
14.9 |
4.8% |
Slight decline if generics prevail |
Increased generic penetration |
| 2025 |
15.6 |
4.8% |
$8–$9 (generic average) |
Cost pressures, policy shifts |
| 2026 |
16.3 |
4.8% |
$7–$8 |
Market consolidation, biosimilars |
| 2027 |
17.1 |
4.8% |
$6–$8 |
Further generic competition |
| 2028 |
17.9 |
4.8% |
$5–$7 |
Price erosion, biosimilar entry |
Key Risks and Opportunities
-
Risks:
- Tighter regulations on opioids reducing prescriptions.
- Litigation and legal restrictions impacting supply and pricing.
- Potential development of abuse-deterrent formulations reducing demand for traditional ER morphine.
-
Opportunities:
- Expansion into emerging markets with less regulatory oversight.
- Development of abuse-deterrent formulations with patent protection.
- Integration into multimodal pain management protocols.
Key Takeaways
- The market for extended-release morphine like Avinza remains significant, particularly in clinical settings requiring sustained analgesia.
- Price stability is expected in the short term, with downward pressure from generic competition and regulatory constraints.
- Market growth hinges on evolving prescribing policies, societal attitudes toward opioids, and potential advances in abuse-deterrent technologies.
FAQs
-
When will generic versions of Avinza likely enter the market?
Generic versions have been available since 2009 for certain formulations. Future entry depends on patent litigation and formulation-specific patent protections. Despite patent expirations, specific formulations may still be protected, delaying generic entry.
-
How does the regulatory environment affect Avinza pricing?
Stricter prescribing guidelines and increased oversight limit demand but do not significantly impact manufacturing costs or prices directly. Reimbursement rates and coverage policies influence payor and patient costs.
-
What factors could alter price projections for ER morphine products?
Introduction of abuse-deterrent formulations, patent litigation outcomes, regulatory restrictions, and shifts towards non-opioid pain therapies could all influence prices.
-
Are there emerging alternatives to ER morphine for pain management?
Yes. Non-opioid analgesics, nerve block techniques, and novel biologics are under development, which could reduce dependence on ER opioids.
-
How does market demand differ across regions?
The U.S. commands the largest share of opioid analgesic prescriptions, with expanding markets in Asia-Pacific and Latin America, albeit with differing regulatory and healthcare infrastructure.
References
[1] Grand View Research. "Opioid Analgesics Market Size & Share Report, 2023–2030."
[2] IQVIA. "Prescription Trends and Market Dynamics," 2022.
[3] FDA. "Opioid Analgesics Regulatory Overview," 2023.
[4] U.S. Substance Abuse and Mental Health Services Administration (SAMHSA). "Pain Management and Opioid Use," 2022.
